Meningitis

β-N-Acetylhexosaminidase, Streptococcus pneumoniae is a cell surface virulence factor of Streptococcus pneumoniae, which contains two synergistically acting GH20 domains (with higher activity in GH20-2). β-N-Acetylhexosaminidase, Streptococcus pneumoniae specifically recognizes and hydrolyzes substrates with β(1,2) glycosidic bonds via Trp-443 and Tyr-482 residues. β-N-Acetylhexosaminidase, Streptococcus pneumoniae catalyzes the hydrolysis of β(1,2)-linked N-acetylglucosamine groups and related disaccharides, and promotes persistent colonization of bacteria in the airway by modifying host defense molecules and releasing monosaccharides for bacterial growth. β-N-Acetylhexosaminidase, Streptococcus pneumoniae can be used in studies related to Streptococcus pneumoniae infection, acute pneumonia, otitis media and meningitis.

D-Captopril is a NDM-1 inhibitor and a competitive BlaB inhibitor, with an IC₅₀ value of 21.8 µM against NDM-1 and a K_i of 70-100 µM against BlaB. D-Captopril synergistically reduces the minimum inhibitory concentration of Meropenem (HY-13678) against NDM-1-expressing bacteria. D-Captopril binds to BcII via its thiolate sulfur atom and carboxylate group, altering metal ion occupancy and modulating Cd²⁺ binding affinity. D-Captopril can be used in the research of neonatal meningitis, sepsis and bacterial infections.

Antifungal agent 141, a Phenoxazine (HY-34463) derivative, is an antifungal agent. Antifungal agent shows potent antifungal activity in Cryptococcus neoformans and Candida albicans with MIC values of 2 and 4 µg/mL. Antifungal agent 141 can be used for the research of cryptococcal meningitis.